TWI883107B - 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑 - Google Patents

用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑 Download PDF

Info

Publication number
TWI883107B
TWI883107B TW110101887A TW110101887A TWI883107B TW I883107 B TWI883107 B TW I883107B TW 110101887 A TW110101887 A TW 110101887A TW 110101887 A TW110101887 A TW 110101887A TW I883107 B TWI883107 B TW I883107B
Authority
TW
Taiwan
Prior art keywords
btk inhibitor
pyridin
phenoxyphenyl
imidazo
acryloylpiperidin
Prior art date
Application number
TW110101887A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140002A (zh
Inventor
趙美亨
提摩西 透納
艾力克 瓦爾斯特倫
Original Assignee
美商普林斯匹亞生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普林斯匹亞生物製藥公司 filed Critical 美商普林斯匹亞生物製藥公司
Publication of TW202140002A publication Critical patent/TW202140002A/zh
Application granted granted Critical
Publication of TWI883107B publication Critical patent/TWI883107B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110101887A 2020-01-20 2021-01-19 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑 TWI883107B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062963238P 2020-01-20 2020-01-20
US62/963,238 2020-01-20
US202062970502P 2020-02-05 2020-02-05
US62/970,502 2020-02-05
US202063013895P 2020-04-22 2020-04-22
US63/013,895 2020-04-22

Publications (2)

Publication Number Publication Date
TW202140002A TW202140002A (zh) 2021-11-01
TWI883107B true TWI883107B (zh) 2025-05-11

Family

ID=74626161

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110101887A TWI883107B (zh) 2020-01-20 2021-01-19 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑

Country Status (12)

Country Link
US (2) US11969418B2 (https=)
EP (1) EP4093397A1 (https=)
JP (2) JP2023510604A (https=)
KR (1) KR20220130179A (https=)
CN (1) CN115348862A (https=)
AU (1) AU2021209608A1 (https=)
BR (1) BR112022014058A2 (https=)
CA (1) CA3168146A1 (https=)
IL (1) IL294560A (https=)
MX (1) MX2022008875A (https=)
TW (1) TWI883107B (https=)
WO (1) WO2021150476A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
AU2021398051A1 (en) * 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A4 (en) * 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
CN117412749A (zh) * 2021-05-21 2024-01-16 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
WO2022257845A1 (zh) * 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
CA3260159A1 (en) * 2022-06-30 2024-01-04 Principia Biopharma Inc. Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
EP4601647A1 (en) * 2022-10-11 2025-08-20 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis
AU2023408758A1 (en) * 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
JP2026505764A (ja) 2023-02-01 2026-02-18 プリンシピア バイオファーマ インコーポレイテッド 多発性硬化症を診断及び治療する方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2465328C (en) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
TW200911803A (en) 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CN103502249A (zh) 2011-05-17 2014-01-08 普林斯匹亚生物制药公司 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013191965A1 (en) 2012-06-18 2013-12-27 Principia Biopharma Inc. Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
WO2015132799A2 (en) 2014-02-03 2015-09-11 Cadila Healthcare Limited Novel heterocyclic compounds
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
SI3377484T1 (sl) 2015-11-17 2024-02-29 Merck Patent Gmbh Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo
BR112022014058A2 (pt) 2020-01-20 2022-09-13 Genzyme Corp Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
EP4328226A4 (en) 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 Principia Biopharma Inc Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019 2019/03/01 https://www.nasdaq.com/press-release/principia-biopharma-presents-phase-1-clinical-data-cns-penetrating-btk-inhibitor

Also Published As

Publication number Publication date
WO2021150476A1 (en) 2021-07-29
TW202140002A (zh) 2021-11-01
EP4093397A1 (en) 2022-11-30
MX2022008875A (es) 2022-08-11
CA3168146A1 (en) 2021-07-29
US20240366585A1 (en) 2024-11-07
US20210244720A1 (en) 2021-08-12
CN115348862A (zh) 2022-11-15
US11969418B2 (en) 2024-04-30
JP2023510604A (ja) 2023-03-14
KR20220130179A (ko) 2022-09-26
BR112022014058A2 (pt) 2022-09-13
IL294560A (en) 2022-09-01
AU2021209608A1 (en) 2022-09-15
JP2026001038A (ja) 2026-01-06

Similar Documents

Publication Publication Date Title
TWI883107B (zh) 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
KR20190039769A (ko) 호산구성 식도염의 치료 방법
US20250262193A1 (en) Therapeutic Tyrosine Kinase Inhibitors For Multiple Sclerosis and Myasthenia Gravis
KR20230004618A (ko) 전신성 과염증 반응을 수반하는 병태 치료에 사용하기 위한 에클리타세르팁
TW202446375A (zh) 用於治療高蛋白尿慢性腎病的齊泊騰坦和達格列淨之組合
US20260027100A1 (en) Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
RU2842678C1 (ru) Терапевтические ингибиторы тирозинкиназы для лечения рецидивирующего рассеянного склероза (rms)
US20240173313A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
US20260060974A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
RU2821032C1 (ru) Способы лечения заболеваний, связанных с рецептором s1p1
AU2024318637A1 (en) Obefazimod for treatment of ulcerative colitis